Ads
related to: License-Agreement and Clinical Development
Search results
Financial Analysis: Shattuck Labs (NASDAQ:STTK) vs. Ovid Therapeutics (NASDAQ:OVID)
ETF DAILY NEWS· 7 days agoOvid Therapeutics (NASDAQ:OVID – Get Free Report) and Shattuck Labs (NASDAQ:STTK – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare ...
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Digital Journal· 2 days ago"Thaminda's extensive experience in advancing corporate strategy, business development and strengthening strategic partnerships in specific areas will be a tremendous asset ...
Bristol-Myers Q1 Loss Narrower Than Expected, Sales Beat - ADMA Biologics (NASDAQ:ADMA), ANI...
Benzinga· 20 hours agoBristol-Myers Squibb Company BMY reported an adjusted loss per share of $4.40, narrower than the...
Can We Prompt Hair to Grow? – UCI Beall Applied Innovation
UC Irvine Today· 6 days agoRecognizing the limitations in the current market, Plikus saw the entrepreneurial potential of his research, and worked with the Cove to attract interest from industry. Around the same time, ...
Interested in Opening a Medical Spa? Here’s What You Need to Know
The National Law Review· 4 days agoIn response, many providers and investors in the health care industry are seeing opportunities to open or invest in a medical spa. One of the first elements to consider when opening a medical ...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against...
Morningstar· 2 days agoBragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Checkpoint Therapeutics ...
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
Zacks· 2 days agoBristol-Myers Squibb Company (BMY Quick QuoteBMY - Free Report) reported an adjusted loss per share of $4.40, narrower than the Zacks Consensus Estimate of a loss of $4.53 per share. In the ...
ImmPACT Bio to Present New Ex Vivo Preclinical Data for Bispecific Claudin 18.2/TGF-β CAR T Program...
Napa Valley Register· 4 days agoImmPACT Bio USA Inc. (ImmPACT Bio), a clinical-stage biopharmaceutical company developing a new generation of cellular therapies that have the potential to bring transformational ...
Recurrence Data for Narrow Band Imaging™ (NBI™) Technology Show Value in the Fight Against...
Journal Gazette & Times-Courier· 2 days ago"Without dyes, without any change to the patient's standard cystoscopy, and with only a push of a button, urologists can better visualize a lesion, and potentially contribute to reduced recurrence ...
CMMI’s Innovations in Behavioral Health: Promoting Physical and Mental Well-being | JD Supra
JD Supra· 3 days agoSummary- On January 18, 2024, the Center for Medicare and Medicaid Innovation (CMMI) at the Centers for Medicare and Medicaid Services (...
